Literature DB >> 27319009

Management of hyperthyroidism due to Graves' disease: frequently asked questions and answers (if any).

L Bartalena1, L Chiovato2, P Vitti3.   

Abstract

Graves' disease is the most common cause of hyperthyroidism in iodine-replete areas. Although progress has been made in our understanding of the pathogenesis of the disease, no treatment targeting pathogenic mechanisms of the disease is presently available. Therapies for Graves' hyperthyroidism are largely imperfect because they are bound to either a high rate of relapsing hyperthyroidism (antithyroid drugs) or lifelong hypothyroidism (radioiodine treatment or thyroidectomy). Aim of the present article is to offer a practical guidance to the reader by providing evidence-based answers to frequently asked questions in clinical practice.

Entities:  

Keywords:  Agranulocytosis; Alemtuzumab; Childhood; Graves’ disease; Graves’ orbitopathy; Hyperthyroidism; Methimazole; Pregnancy; Propylthiouracil; Radioiodine; Thionamides; Thyroidectomy

Mesh:

Year:  2016        PMID: 27319009     DOI: 10.1007/s40618-016-0505-x

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  98 in total

1.  Clinical features of patients with Graves' disease undergoing remission after antithyroid drug treatment.

Authors:  P Vitti; T Rago; L Chiovato; S Pallini; F Santini; E Fiore; R Rocchi; E Martino; A Pinchera
Journal:  Thyroid       Date:  1997-06       Impact factor: 6.568

2.  Hyperthyroidism and other causes of thyrotoxicosis: management guidelines of the American Thyroid Association and American Association of Clinical Endocrinologists.

Authors:  Rebecca S Bahn Chair; Henry B Burch; David S Cooper; Jeffrey R Garber; M Carol Greenlee; Irwin Klein; Peter Laurberg; I Ross McDougall; Victor M Montori; Scott A Rivkees; Douglas S Ross; Julie Ann Sosa; Marius N Stan
Journal:  Thyroid       Date:  2011-04-21       Impact factor: 6.568

3.  A 2013 European survey of clinical practice patterns in the management of Graves' disease.

Authors:  L Bartalena; H B Burch; K D Burman; G J Kahaly
Journal:  Clin Endocrinol (Oxf)       Date:  2015-01-09       Impact factor: 3.478

4.  Increased cardiovascular and cancer mortality after radioiodine treatment for hyperthyroidism.

Authors:  Saara Metso; Pia Jaatinen; Heini Huhtala; Anssi Auvinen; Heikki Oksala; Jorma Salmi
Journal:  J Clin Endocrinol Metab       Date:  2007-03-20       Impact factor: 5.958

Review 5.  An update on the medical treatment of Graves' hyperthyroidism.

Authors:  Michele Marinò; Francesco Latrofa; Francesca Menconi; Luca Chiovato; Paolo Vitti
Journal:  J Endocrinol Invest       Date:  2014-09-04       Impact factor: 4.256

Review 6.  Controversies in the management of Graves' disease in children.

Authors:  S A Rivkees
Journal:  J Endocrinol Invest       Date:  2016-05-06       Impact factor: 4.256

Review 7.  Comparative effectiveness of therapies for Graves' hyperthyroidism: a systematic review and network meta-analysis.

Authors:  Vishnu Sundaresh; Juan P Brito; Zhen Wang; Larry J Prokop; Marius N Stan; Mohammad H Murad; Rebecca S Bahn
Journal:  J Clin Endocrinol Metab       Date:  2013-07-03       Impact factor: 5.958

8.  Cancer Incidence and Mortality in Patients Treated Either With RAI or Thyroidectomy for Hyperthyroidism.

Authors:  Essi Ryödi; Saara Metso; Pia Jaatinen; Heini Huhtala; Rauni Saaristo; Matti Välimäki; Anssi Auvinen
Journal:  J Clin Endocrinol Metab       Date:  2015-08-11       Impact factor: 5.958

Review 9.  Extrathyroidal manifestations of Graves' disease: a 2014 update.

Authors:  Luigi Bartalena; Vahab Fatourechi
Journal:  J Endocrinol Invest       Date:  2014-06-10       Impact factor: 4.256

10.  Cancer risk after medical exposure to radioactive iodine in benign thyroid diseases: a meta-analysis.

Authors:  Trinh Trung Hieu; Anthony W Russell; Ross Cuneo; Justin Clark; Tomas Kron; Per Hall; Suhail A R Doi
Journal:  Endocr Relat Cancer       Date:  2012-09-14       Impact factor: 5.678

View more
  28 in total

1.  How does neural monitoring help during thyroid sugery for Graves' disease?

Authors:  Le Zhou; Gianlorenzo Dionigi; Alessandro Pontin; Antonella Pino; Ettore Caruso; Che-Wei Wu; Hui Sun; Ralph P Tufano; Hoon Yub Kim
Journal:  J Clin Transl Endocrinol       Date:  2018-11-20

2.  Features and outcome of differentiated thyroid carcinoma associated with Graves' disease: results of a large, retrospective, multicenter study.

Authors:  P Premoli; M L Tanda; E Piantanida; G Veronesi; D Gallo; E Masiello; S Rosetti; C Cusini; F Boi; J Bulla; R Rodia; S Mariotti; V Capelli; M Rotondi; F Magri; L Chiovato; R Rocchi; M C Campopiano; R Elisei; P Vitti; F Barbato; T Pilli; M G Castagna; F Pacini; L Bartalena
Journal:  J Endocrinol Invest       Date:  2019-07-20       Impact factor: 4.256

3.  Teprotumumab: a new avenue for the management of moderate-to-severe and active Graves' orbitopathy?

Authors:  E Piantanida; L Bartalena
Journal:  J Endocrinol Invest       Date:  2017-06-20       Impact factor: 4.256

4.  Maria Carolina of Austria, Queen of Naples and Sicily: a possible case of Graves' orbitopathy.

Authors:  C Di Giacomo; F Trimarchi; L Bartalena
Journal:  J Endocrinol Invest       Date:  2016-11-03       Impact factor: 4.256

5.  Usefulness of TSH receptor antibodies as biomarkers for Graves' ophthalmopathy: a systematic review.

Authors:  S Seo; M Sánchez Robledo
Journal:  J Endocrinol Invest       Date:  2018-09-07       Impact factor: 4.256

Review 6.  Preoperative management in patients with Graves' disease.

Authors:  Eliana Piantanida
Journal:  Gland Surg       Date:  2017-10

7.  Antithyroid drug treatment for Graves' disease: baseline predictive models of relapse after treatment for a patient-tailored management.

Authors:  E Masiello; G Veronesi; D Gallo; P Premoli; E Bianconi; S Rosetti; C Cusini; J Sabatino; S Ippolito; E Piantanida; M L Tanda; L Chiovato; W M Wiersinga; L Bartalena
Journal:  J Endocrinol Invest       Date:  2018-06-26       Impact factor: 4.256

8.  Apparent biochemical thyrotoxicosis due to assay interference by high-dose biotin given for multiple sclerosis.

Authors:  C Cusini; L Sassi; G De Paola; E Piantanida
Journal:  J Endocrinol Invest       Date:  2017-05-06       Impact factor: 4.256

9.  Use of low-dose radioiodine ablation for Graves' orbitopathy: results of a pilot, perspective study in a small series of patients.

Authors:  M Leo; E Sabini; I Ionni; A Sframeli; B Mazzi; F Menconi; E Molinaro; F Bianchi; F Brozzi; P Santini; R Elisei; M Nardi; P Vitti; C Marcocci; M Marinò
Journal:  J Endocrinol Invest       Date:  2017-08-30       Impact factor: 4.256

10.  Low regulatory T cell and high IL-17 mRNA expression in a mouse Graves' disease model.

Authors:  Q Yuan; Y Zhao; X Zhu; X Liu
Journal:  J Endocrinol Invest       Date:  2016-11-07       Impact factor: 4.256

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.